A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Metreleptin (Primary) ; Pramlintide (Primary)
  • Indications Obesity; Overweight
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Oct 2011 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov record.
    • 19 Oct 2009 According to an Amylin Pharmaceuticals media release, results will be reported at Obesity 2009, the 27th Annual Scientific Meeting of the Obesity Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top